➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Merck
Harvard Business School
McKinsey
Dow

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FIRAZYR

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Firazyr

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00912093 A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Completed Shire Phase 3 2009-06-01 This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
NCT00997204 EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed Jerini AG Phase 3 2009-09-01 This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
NCT00997204 EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed Shire Phase 3 2009-09-01 This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Firazyr

Condition Name

Condition Name for Firazyr
Intervention Trials
Hereditary Angioedema 3
Hereditary Angioedema (HAE) 2
COVID-19 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Firazyr
Intervention Trials
Angioedema 7
Angioedemas, Hereditary 5
Critical Illness 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Firazyr

Trials by Country

Trials by Country for Firazyr
Location Trials
United States 71
Canada 6
Australia 5
France 5
Israel 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Firazyr
Location Trials
California 7
Pennsylvania 5
Maryland 4
Texas 4
Ohio 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Firazyr

Clinical Trial Phase

Clinical Trial Phase for Firazyr
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Firazyr
Clinical Trial Phase Trials
Completed 5
Not yet recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Firazyr

Sponsor Name

Sponsor Name for Firazyr
Sponsor Trials
Shire 5
University of Alabama at Birmingham 1
University of Southern California 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Firazyr
Sponsor Trials
Other 16
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Baxter
Medtronic
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.